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Identity 
Other names: CC-CKR-2; CCR2A; CCR2B; CD192; 
CKR2; CKR2A; CKR2B; CMKBR2; FLJ78302; MCP-
1-R; MGC103828; MGC111760; MGC168006 




CCR2 is a member of the beta chemokine receptor 
family. CCR2 is a seven transmembrane protein similar 
to G protein-coupled receptors. This gene encodes two 
isoforms of a receptor for monocyte chemoattractant 
protein-1, a chemokine which specifically mediates 
monocyte chemotaxis. Monocyte chemoattractant 
protein-1 is involved in monocyte infiltration in 
inflammatory diseases such as rheumatoid arthritis as 
well as in the inflammatory response against tumors. 
The receptors encoded by this gene mediate agonist-
dependent calcium mobilization and inhibition of 
adenylyl cyclase. This gene is located in the chemokine 
receptor gene cluster region including CCR1, CCRL2, 
CCR3, CCR5 and CCXCR1 on chromosome 3p. 
Description 
Size: 7195 bases. 
2 isoforms: 
- C-C chemokine receptor type 2 isoform A. 
CCDS43078.1 
- C-C chemokine receptor type 2 isoform B. 
CCDS46813.1 
Transcription 
Homo sapiens chemokine (C-C motif) receptor 2 
(CCR2), transcript variant A, mRNA: 2689 bp. 
Homo sapiens chemokine (C-C motif) receptor 2 
(CCR2), transcript variant B, mRNA: 2335 bp. 
Pseudogene 
No pseudogenes have been reported for CCR2. 
Protein 
Note 
Chemokine receptors are cytokine receptors found on 
the surface of cells, which interact with a type of 
cytokine called a chemokine. They have a 7 
transmembrane structure and couple to G-protein for 
signal transduction within a cell, making them 
members of a large protein family of G protein-coupled 
receptors. Following interaction with their specific 
chemokine ligands, chemokine receptors trigger a flux 
in intracellular calcium (Ca2+) ions (calcium signaling). 
This causes cell responses, including the onset of a 
process known as chemotaxis that traffics the cell to a 
desired location within the organism. 
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Structure of CCR2. The typical serpentine structure is depicted with three extracellular (top) and three intracellular (bottom) loops and 
seven transmembrane domains. 
 
Chemokine receptors share many common structural 
features; they are composed of about 350 amino acids 
that are divided into a short and acidic N-terminal end, 
seven helical transmembrane domains with three 
intracellular and three extracellular hydrophilic loops, 
and an intracellular C-terminus containing serine and 
threonine residues that act as phosphorylation sites 
during receptor regulation. The first two extracellular 
loops of chemokine receptors are linked together by 
disulfide bonding between two conserved cysteine 
residues. The N-terminal end of a chemokine receptor 
binds to chemokine(s) and is important for ligand 
specificity. G-proteins couple to the C-terminal end, 
which is important for receptor signaling following 
ligand binding. 
Description 
374 amino acids; 41915 Da. 
Expression 
Peripheral blood monocytes, activated T cells, B cells 
and immature dendritic cells. 
Localisation 
Cell membrane; multi-pass membrane protein. 
Function 
Receptor for the MCP-1/CCL2, MCP-3/CCL7 and 
MCP-4/CCL13 chemokines. Transduces a signal by 
increasing the intracellular calcium ions level. 
Alternative coreceptor with CD4 for HIV-1 infection. 
Homology 
CCR2 proteins contains amino acid sequence 
homology to other C-C chemokines. CCR1 (56%), 




In a cohort of 80 patients with Multiple Myeloma 
(MM), patients with active disease showed significant 
lower expression of CCR1, CCR2 and CXCR4 than 
patients with non-active disease. 
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Oncogenesis 
CCR1 and CCR2 are overexpressed in myeloma cells 
compared to normal B cells. Osteoclasts express genes 
coding for CCR2 chemokines specifically (CCL2, 
CCL7, CCL8, and CCL13) and high CCR2 gene 
expression in myeloma cells is associated with 
increased bone lesions in MM patients. CCR2 is 
significantly overexpressed in MM cells compared to 
normal bone marrow plasma cells. Osteoclasts can 
directly recruit MMC by CCR2 chemokines 
production, promote MMC survival, growth, and drug 
resistance by producing various growth factors. MMC 
will promote osteoclast progenitor recruitment and 
differentiation producing CCL3, MIP-1beta, and 
CXCL12 chemokines, IGF-1, and increasing RANKL 
production by stromal cells. Osteoclasts are the main 
cells in the BM environment that produce various 




98 untreated primary neuroblastomas from patients 
with metastatic disease were analyzed for tumor-
infiltrating iNKTs (Valpha24-Jalpha18-invariant 
natural killer T cells) using RT-PCR and 
immunofluorescent microscopy. 53% of tumors 
contained iNKTs. CCR2 is more frequently expressed 
by iNKT compared to T cells and natural killer cells 
from blood. iNKTs migrate toward neuroblastoma cells 
in a CCL2-dependent manner, preferentially infiltrating 




MCP-1 may play a role in tumor angiogenesis and 
early tumor growth of human malignant melanoma by 
inducing VEGF and inflammatory cytokines 
production (IL-1alpha and TNFalpha by the tumor-
associated macrophages (TAM) and 




The pleiotropic roles of CCL2 in the development of 
prostate cancer are mediated through its receptor, 
CCR2. An association between prostate cancer 
progression and CCR2 expression was demonstrated on 
tissue microarray specimens of patients. CCR2 mRNA 
and protein were significantly overexpressed within 
prostate cancer metastatic tissues compared to localized 
prostate cancer and benign prostate tissue. CCR2 
overexpression was also associated with higher 
Gleason score and higher clinical pathologic stages. 
Oncogenesis 
CCL2 support prostate cancer cell survival via 
PI3K/AKT in vitro. CCL2 derived from human bone 
marrow endothelial cells induces PC-3 cell line 
transendothelial cell migration via activation of the 
small GTPase Rac. In a cell co-culture system, prostate 
cancer cell-conditioned medium induces CCL2 
overexpression in endothelial cells and osteoblasts. In 
osteoblasts, this secretion is mediated in part by 
parathyroid hormone-related protein. 
 
In mouse model, neutralizing antibody against CCL2 
inhibits prostate cancer PC-3 and VCaP growth in 
bone. Same results were obtained with CCL2 
knockdown. CCL2 induces surviving expression in 




Overexpression of the chemokine CCL2 is frequently 
associated with advanced tumor stage and metastatic 
relapse in breast cancer. 
Oncogenesis 
Overexpression of CCL2 promotes breast cancer 
metastasis to both lung and bone in mice. Blocking 
CCL2 with a neutralizing antibody reduced lung and 
bone metastases. The enhancement of lung metastases 
by CCL2 was associated with increased macrophage 
infiltration. In bone, it was associated with osteoclast 
differentiation. CCL2 produced by breast tumor cells 
activates CCR2 positive stromal cells of monocytic 
origin (including macrophages and preosteoclasts) 
leading to metastases in lung and bone. 
Esophageal carcinoma 
Oncogenesis 
CCL2 is expressed by tumor cells of esophageal 
squamous cell carcinoma. CCL2 produced by tumor 
cell and CCR2 expressed on vascular endothelial cells 




CCL2 produced by human gastric carcinoma cells is 
involved in angiogenesis via macrophage recruitment 
and activation via CCR2. CCL2 produced by gastric 
carcinoma cells induces tumor growth in ectopic 
xenografts and increased tumorigenicity and induced 
lymph node metastases and ascites in orthotopic 
xenografts. 
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